Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fate Therapeutics (FATE) Interest & Investment Income (2016 - 2025)

Historic Interest & Investment Income for Fate Therapeutics (FATE) over the last 13 years, with Q3 2025 value amounting to $2.6 million.

  • Fate Therapeutics' Interest & Investment Income fell 4197.84% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.7 million, marking a year-over-year decrease of 2873.01%. This contributed to the annual value of $17.3 million for FY2024, which is 59.35% up from last year.
  • Latest data reveals that Fate Therapeutics reported Interest & Investment Income of $2.6 million as of Q3 2025, which was down 4197.84% from $2.9 million recorded in Q2 2025.
  • Fate Therapeutics' Interest & Investment Income's 5-year high stood at $4.8 million during Q2 2024, with a 5-year trough of $289000.0 in Q3 2021.
  • Moreover, its 5-year median value for Interest & Investment Income was $2.9 million (2025), whereas its average is $2.7 million.
  • In the last 5 years, Fate Therapeutics' Interest & Investment Income crashed by 6121.4% in 2021 and then soared by 86969.7% in 2022.
  • Quarter analysis of 5 years shows Fate Therapeutics' Interest & Investment Income stood at $297000.0 in 2021, then skyrocketed by 869.7% to $2.9 million in 2022, then skyrocketed by 53.26% to $4.4 million in 2023, then decreased by 12.23% to $3.9 million in 2024, then plummeted by 33.53% to $2.6 million in 2025.
  • Its Interest & Investment Income stands at $2.6 million for Q3 2025, versus $2.9 million for Q2 2025 and $3.3 million for Q1 2025.